Gentian Diagnostics ASA, a fast-growing developer and manufacturer of innovative and efficient diagnostics for better treatment decisions, has completed the technical development of its novel SARS-Cov-2 antibody immunoassay. This will be the first assay available on high-throughput open-access clinical chemistry platforms for detection of antibodies against SARS CoV-2 virus. The assay will be easily accessible and efficient, and holds potential to speed up the determination of immunisation status in society and support vaccination efforts.
“The recent resurgence of Covid-19 cases highlights the need for reliable high-throughput tests to manage the pandemic. With up to 2000 tests per hour we are confident that our new SARS-Cov-2 test can increase capacity and laboratory efficiency significantly. Our assay can be used on all instrument platforms with no additional infrastructure or workflow costs.”, says CEO Hilja Ibert in Gentian Diagnostics.
+47 919 05 242 (mobile)
Njaal Kind, CFO and COO
+47 919 06 525 (mobile)
Gentian Diagnostics (OSE: GENT), founded in 2001, develops and manufactures high-quality, in vitro diagnostic reagents. Gentian’s expertise and focus lies within immunochemistry, specifically infections, inflammations, kidney failures and congestive heart failures. By converting existing and clinically relevant biomarkers to the most efficient automated, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian is based in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA and China. For more information, please visit www.gentian.com.